Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming virtual investor conferences. The first is the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET. The second is the Barclays Global Healthcare Conference on March 10, 2021, at 11:30 a.m. ET. Live webcasts and archived replays will be available for 30 days on their website. Travere focuses on developing therapies for rare diseases, engaging with the community to understand their needs and deliver impactful treatments.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +0.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March:
SVB Leerink 10th Annual Global Healthcare Conference
Date: Wednesday, February 24, 2021
Time: 1:00 p.m. ET
Barclays Global Healthcare Conference
Date: Wednesday, March 10, 2021
Time: 11:30 a.m. ET
Live webcasts will be available at https://ir.travere.com/events-presentations and archived replays will be accessible for up to 30 days.
About Travere Therapeutics
At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@travere.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.